SEATTLE, July 22, 2021 /PRNewswire/ -- Volpara
Health, a global health technology software leader
providing an integrated breast care platform for the delivery of
personalized breast care, has signed
an agreement with Invitae Corporation, a leader
in medical genetics, to bring Invitae's genetic
testing services to Volpara's customers in the
United States.
Volpara's United States customers will gain access
to Invitae's comprehensive genetic
testing services within Volpara's software
workflow. Volpara plans to create
an integrated ordering process
for Invitae genetic
testing services within its suite of products
to provide women with additional access to comprehensive genetic
testing services through a variety of clinical settings.
Customers can
utilize Volpara's market-leading breast cancer risk
assessment software to confidently make informed
decisions for triaging patients to supplemental imaging
and/or genetic testing based
on their personalized risk. Risk assessment is
also required by insurance companies in the United
States to justify reimbursement for additional
testing. Along with supplemental screening, such as
ultrasound and MRI, genetic testing assists in earlier
cancer detection and is critical in reducing treatment
costs and increasing the chances of survival.
"Volpara continues to be proud of its major
role in improving access to genetic testing and risk
assessment critical to drive adoption of personalized breast
screening in the United
States.
Our relationship with Invitae adds a prominent
lab to the genetic services available through our breast
health platform and will allow us to
offer increased value to customers by ensuring
that the right patients get seamless access to
the right genetic testing at the right
time," said Dr. Ralph Highnam, Group CEO
of Volpara.
"While the value of genetic information in cancer care is well
established, the ability to combine genetics with breast density
and other forms of risk assessment to guide patient care remains
underutilized," said Robert
Nussbaum, M.D., chief medical officer of Invitae. "In
working with Volpara, we want to make it easier for clinicians and
oncologists to access genetic testing services to ensure that their
patients have comprehensive and personalized medical information to
better inform their healthcare decisions.
About Invitae
Invitae Corporation (NYSE:
NVTA) is a leading medical genetics company whose mission is
to bring comprehensive genetic information into mainstream medicine
to improve healthcare for billions of people. Invitae's goal is to
aggregate the world's genetic tests into a single service with
higher quality, faster turnaround time, and lower prices. For more
information, visit the company's website at invitae.com.
About Volpara
Volpara provides an advanced AI software
platform that works with a healthcare provider's expertise to
enable a high-quality, optimized, and personalized cancer screening
experience. From the time a patient enters a clinic to the moment
they obtain key results, the Volpara Breast Health Platform
collects and analyzes information to better understand a patient's
breast cancer risk, while also objectively evaluating image quality
and workflow-improvement opportunities. These capabilities are
being extended to lung cancer screening. The Volpara Breast Health
Platform is supported by numerous patents, trademarks, and
regulatory registrations including FDA clearance and CE marking,
and is validated by a volume of peer-reviewed publications
unrivaled in the breast screening industry. For more information,
visit https://www.volparahealth.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volpara-collaborates-with-invitae-corporation-leading-genetics-company-301339165.html
SOURCE Volpara Health